Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400372 | 1.00 | S1PR4 (0.52) | S1PR4HTTALDH1A1HIF1ACYP19A1 | |
| SCHEMBL30672731 | 0.88 | S1PR4 (0.66) | S1PR4HTTALDH1A1HIF1ACYP19A1 | |
| SCHEMBL3441990 | 0.88 | S1PR4 (0.66) | S1PR4HTTALDH1A1HIF1ACYP19A1 | |
| SCHEMBL16848696 | 0.86 | CYP19A1 (0.61) | S1PR4HTTALDH1A1HIF1ACYP19A1 | |
| SCHEMBL20335461 | 0.86 | HTT (0.49) | S1PR4HTTALDH1A1HIF1ACYP19A1 | |
| SCHEMBL2002273 | 0.86 | MAPT (0.55) | S1PR4HTTALDH1A1CYP19A1TDP1 | |
| SCHEMBL12518698 | 0.84 | S1PR4 (0.62) | S1PR4ALDH1A1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL21644480 | 0.83 | TSHR (0.62) | S1PR4HTTALDH1A1HIF1ACYP19A1 | |
| SCHEMBL8926446 | 0.83 | ALDH1A1 (0.49) | S1PR4HTTALDH1A1HIF1ACYP19A1 | |
| SCHEMBL30729439 | 0.83 | HTT (0.66) | S1PR4HTTALDH1A1CYP19A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4186901-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | Cytosinlab Therapeutics Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| CN-110467637-B | Bisaminyl chloropyrimidine compound containing phosphine oxide substituted aniline, preparation method and application thereof | 北京赛特明强医药科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | S1PR4 2721/4885HTT 1602/4885ALDH1A1 1694/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | S1PR4 2940/4885HTT 3484/4885ALDH1A1 2716/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | S1PR4 2721/4885HTT 1602/4885ALDH1A1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.